Mounjaro Recall: What UK Patients Need to Know Right Now

Why "recall" searches spike, and what the MHRA has actually published

Mounjaro carries a Black Triangle (▼) designation from the MHRA. This is standard for newer medicines and means the regulator actively collects extra post-market safety data, it says nothing about the medicine being unsafe or under threat of withdrawal. Black Triangle status is published openly in the BNF entry for tirzepatide and is one reason UK prescribers follow patients closely during treatment.

The most substantive MHRA communication about GLP-1 medicines in recent months was a Drug Safety Update published on 29 January 2026. It highlighted acute pancreatitis as an infrequent but serious known side effect across the GLP-1 class. Patients were advised to seek urgent medical attention for severe, persistent stomach pain that radiates to the back, particularly if accompanied by vomiting. This is a monitoring and prescriber-awareness communication; it did not alter Mounjaro's licensed status or prompt a product withdrawal. Safety updates of this kind are the system working as it should.

A separate category of concern involves counterfeit tirzepatide pens sold outside the licensed supply chain. The MHRA raided the first UK manufacturing site producing fake tirzepatide pens in Northampton in October 2025, and enforcement action has included the seizure of roughly 20 million doses of illegally traded weight-loss medicines at an estimated street value of around £45 million. These fake products are the real hazard, not genuine Mounjaro supplied through a GPhC-registered pharmacy. Checking whether an online pharmacy appears on the GPhC register takes less than a minute and removes most of that risk entirely.

How Mounjaro's evidence base informs ongoing monitoring

Mounjaro's UK licence rests on the SURMOUNT clinical programme, involving thousands of adults with obesity. SURMOUNT-1, published in the New England Journal of Medicine, demonstrated average body-weight reductions of around 20–21% at the 15 mg dose over 72 weeks. NICE subsequently recommended tirzepatide for weight management in its technology appraisal TA1026, published in December 2024 and updated in September 2025, for adults with a BMI of 35 or above plus at least one weight-related condition. Lower BMI thresholds apply for certain ethnic backgrounds under the same appraisal.

Large, well-conducted trials generate a detailed safety profile, and that profile is what regulators monitor against real-world reports. The SURMOUNT programme identified the GI-led side-effect pattern (nausea, vomiting, diarrhoea and constipation being the most common) which is why prescribers dose up gradually. That monitoring infrastructure is active and ongoing; it does not indicate a problem specific enough to prompt recall. For a broader picture of how Mounjaro works and what the clinical evidence covers, the full detail is worth reading before starting treatment.

What a genuine MHRA recall looks like, and how to spot one

A formal medicine recall in the UK is published as a Drug Alert on the MHRA website and is classified by level (Class 1 being the most serious). Pharmacies receive direct notifications and withdraw the affected batch or product from supply. None of that has occurred for Mounjaro as a whole. If a specific batch recall were ever issued (for a packaging defect, labelling error or quality issue found in a particular lot) it would be narrow, batch-specific, and clearly numbered. Your pharmacy would contact you if your pen was affected. Searching for "Mounjaro recall" and landing on forum speculation or press coverage of counterfeit seizures is not the same as finding a live MHRA Drug Alert.

If you are mid-treatment and have a question about a pen you have already received, the right first step is to call your prescribing pharmacy. If you are considering starting treatment and want to understand what proper clinical oversight looks like, our Mounjaro overview covers the licensed indication, eligibility, and the safety monitoring that comes with every prescription. There is also a useful cost context on our Mounjaro price comparison page if you are weighing up private treatment options.

How to report a concern about a Mounjaro pen

If you have received a pen you suspect is counterfeit (the pen looks different from usual, the pen arrived through an unofficial channel, or the results feel inconsistent) report it to the MHRA via the Yellow Card scheme. The same portal handles suspected side effects and suspect sellers. Do not use a pen you have doubts about; contact your prescriber or our support team first.

Side effects that are new, severe or worsening also warrant a call to your prescriber rather than a search for reassurance online. The pancreatitis symptoms the MHRA highlighted (intense stomach pain spreading to the back) should prompt same-day medical attention, not watchful waiting. Some patients also notice unexpected physical changes while on treatment, and if you have been wondering whether Mounjaro makes you feel cold all the time, that question is covered in detail alongside other commonly reported effects. Many people also find that planning ahead with suitable Mounjaro recipes helps them manage appetite changes and GI symptoms more comfortably, and our Mounjaro recipe guide is a good starting point for ideas that work with the medication rather than against it. For patients curious about the wider landscape of licensed weight-loss treatments in the UK, our team keeps that information current and clinically reviewed.